1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Akorn Inc.
- Allergan Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Eye Infections Therapeutics Market: About this market
The eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.
Global Eye Infections Therapeutics Market: Overview
Rising geriatric population
The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.
Growing adoption of generics
The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global eye infections therapeutics market is highly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.
Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.
Global Eye Infections Therapeutics Market: Overview
Rising geriatric population
The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.
Growing adoption of generics
The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global eye infections therapeutics market is highly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.
Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Akorn Inc.
- Allergan Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Akorn Inc.
- Allergan Plc
- Bausch Health Companies, Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Sanofi
- Santen Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown